Substrate reduction therapy in mouse models of the glycosphingolipidoses

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 358, Issue 1433, 2003, Pages 947-954

  Platt, Frances M ^a   Jeyakumar, Mylvaganam ^a   Andersson, Ulrika ^a   Heare, Tanya ^a   Dwek, Raymond A ^a   Butters, Terry D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Glycosphingolipids; Lysosomal storage diseases; Mouse models; N butyldeoxyglactonojirimycin; N butyldeoxynojirimycin; Substrate reduction therapy

Indexed keywords

BIOCHEMISTRY;

ANIMALIA;

EID: 0038777080     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2003.1279     Document Type: Conference Paper

References (58)

1. Abe, A., Inokuchi, J., Jimbo, M., Shimeno, H., Nagamatsu, A., Shayman, J. A., Shukla, G. S. & Radin, N. S. 1992 Improved inhibitors of glucosylceramide synthase. J. Biochem. Tokyo 111, 191-196.
2. Abed A., Gregory, S., Lee, L., Killen, P. D., Brady, R. O., Kulkarni, A. & Shayman, J. A. 2000 Reduction of globotriaosyl-ceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 105, 1563-1571.
3. Andersson, U., Butters, T. D., Dwek, R. A. & Platt, F. M. 2000 N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyld-eoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59, 821-829.
4. Barranger, J. M. & Novelli, E. A. 2001 Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. 1, 857-867.
5. Beutler, E. & Grabowski, G. 2001 Gaucher disease. In The metabolic and molecular bases of inherited diseases, vol. 3 (ed. C. R. Scriver, A. L. Beadet, D. Valle & W. S. Sly), pp. 3636-3668. New York: McGraw-Hill.
6. Brady, R. O. 2003 Enzyme replacement therapy: conception, chaos and culmination. Phil. Trans. R. Soc. Lond. B 358, 915-919. (DOI 10.1098/rstb.2003.1269.)
7. Brady, R. O., Murray, G. J., Moore, D. F. & Schiffmann, R. 2001 Enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis. 24; 18-24 discussion 11-2.
8. Butters, T., Dwek, R. & Platt, F. 2000 Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders. Chem. Rev. 100, 4683-4696.
9. Butters, T. D., Mellor, H. R., Narita, K., Dwek, R. A. & Platt, F. M. 2003 Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Phil. Trans. R. Soc. Lond. B 358, 927-945. (DOI 10.1098/rstb.2003.1278.)
10. Coetzee, T., Suzuki, K. & Popko, B. 1998 New perspectives on the function of myelin galactolipids. Trends Neurosci. 21, 126-130.
11. Cohen-Tannoudji, M. (and 13 others) 1995 Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mamm. Genome 6, 844-849.
12. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. 2002 Targetting glycosylation as a therapeutic approach. Nature Drug Discovery 1, 65-75.
13. Galbiati, F., Razani, B. & Lisanti, M. P. 2001 Emerging themes in lipid rafts and caveolae. Cell 106, 403-411.
14. Gieselmann, V., Matzner, U., Klein, D., Mansson, J. E., D'Hooge, R., DeDeyn, P. D, Rauch, R. L., Hartmann, D. & Harzer, K. 2003 Gene therapy: prospects for glycolipid storage diseases. Phil. Trans. R. Soc. Lond. B 358, 921-925. (DOI 10.1098/rstb.2003.1277.)
15. Gravel, R. A., Kaback, M. M., Proia, R. L., Sandhoff, K., Suzuki, K. & Suzuki, K. 2001 The GM2 Gangliosidoses. In The metabolic and molecular bases of inherited disease, vol. 3 (ed. C. R. Scriver, A. L. Beadet, D. Valle & W. S. Sly), pp. 3827-3876. New York: McGraw-Hill.
16. Hahn, C. N., Martin, M. D., Schroder, M., Vanier, M. T., Hara, Y., Suzuki, K., Suzuki, K. & dAzzo, A. 1997 Generalized CNS disease and massive G(M1)-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum. Mol. Genet. 6, 205-211.
17. Harder, T. 2003 Formation of functional cell membrane domains: the interplay of lipid- and protein-mediated interactions. Phil. Trans. R. Soc. Lond. B 358, 863-868. (DOI 10.1098/rstb.2003.1274.)
18. Hoogerbrugge, P. M. (and 11 others) 1995 Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments]. Lancet 345, 1398-1402.
19. Ichikawa, S. & Hirabayashi, Y. 1998 Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell. Biol. 8, 198-202.
20. Inokuchi, J. & Radin, N. S. 1987 Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J. Lipid Res. 28, 565-571.
21. Jeyakumar, M., Butters, T. D., Cortina-Borja, M., Proia, R. L., Perry, V. H., Dwek, R. A. & Platt, F. M. 1999 Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 96, 6388-6393.
22. Jeyakumar, M., Norflus, F., Tifft, C. J., Cortina-Borja, M., Butters, T. D., Proia, R. L., Perry, V. H., Dwek, R. A. & Platt, F. M. 2001 Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97, 327-329.
23. Jeyakumar, M., Smith, D., Eliott-Smith, E., Cortina-Borja, M., Reinkensmeier, G., Butters, T., Lemm, T., Sandhoff, K., Perry, V., Dwek, R. & Platt, F. 2002 An inducible mouse model of late onset Tay-Sachs disease. Neurobiol. Dis. 10, 201.
24. Jeyakumar, M., Thomas, R., Elliott-Smith, E., Smith, D. A., van der Spoel, A., d'Azzo, A., Perry, V. H., Butters, T. D., Dwek, R. A. & Platt, F. M. 2003 Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126, 974-987.
25. Kay, A. C., Saven, A., Garver, P., Thurston, D. W., Rosenbloom, B. F. & Beutler, E. 1991 Enzyme replacement therapy in type I Gaucher disease. Trans. Assoc. Am. Physicians 104, 258-264.
26. Lee, L., Abe, A. & Shayman, J. A. 1999 Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274, 14 662-14 669.
27. Liu, Y., Suzuki, K., Reed, J. D., Grinberg, A., Westphal, H., Hoffmann, A., Doting, T., Sandhoff, K. & Proia, R. L. 1998 Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc. Natl Acad. Sci. USA 95, 2503-2508.
28. Lloyd, K. O. & Furukawa, K. 1998 Biosynthesis and functions of gangliosides: recent advances. Glycoconjugate J. 15, 627-636.
29. Max, S. R., Maclaren, N. K., Brady, R. O., Bradley, R. M., Rennels, M. B., Tanaka, J., Garcia, J. H. & Cornblath, M. 1974 GM3 (hematoside) sphingolipodystrophy. N. Engl. J. Med. 291, 929-931.
30. Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. 1999 Prevalence of lysosomal storage disorders. J. Am. Med. Assoc. 281, 249-254.
31. Neufeld, E. F. 1991 Lysosomal storage diseases. A. Rev. Biochem. 60, 257-280.
32. Norflus, F., Tifft, C. J., McDonald, M. P., Goldstein, G., Crawley, J. N., Hoffmann, A., Sandhoff, K., Suzuki, K. & Proia, R. L. 1998 Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest. 101, 1881-1888.
33. Ohshima, T. (and 10 others) 1997 Alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl Acad. Sci. USA 94, 2540-2544.
34. Pastores, G. M. & Thadhani, R. 2001 Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 358, 601-603.
35. Phaneuf, D. (and 15 others) 1996 Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 5, 1-14.
36. Platt, F. M. & Butters, T. D. 1995 Inhibitors of glycosphingo-lipid biosynthesis. Trends Glycosci. Glycotechnol. 7, 495-511.
37. Platt, F. M. & Butters, T. D. 2000 Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases. Exp. Rev. Mol. Med. 2000 http://www-ermm.cbcu.cam.ac.uk.
38. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. 1994a N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365.
39. Platt, F. M., Neises, G. R., Karlsson, G. B., Dwek, R. A. & Butters, T. D. 1994b N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem. 269, 27 108-27 114.
40. Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A. & Butters, T. D. 1997a Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428-431.
41. Platt, F. M., Reinkensmeier, G., Dwek, R. A. & Butters, T. D. 1997b Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J. Biol. Chem. 272, 19 365-19 372.
42. Ringden, O., Groth, C. G., Erikson, A., Granqvist, S., Mansson, J. E. & Sparrelid, E. 1995 Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 59, 864-870.
43. Sandhoff, K. & Klein, A. 1994 Intracellular trafficking of glycosphingolipids: role of sphingolipid activator proteins in the topology of endocytosis and lysosomal digestion. FEBS Lett. 346, 103-107.
44. Sandhoff, K. & Kolter, T. 1996 Topology of glycosphingolipid degradation. Trends Cell Biol. 6, 98-103.
45. Sandhoff, K. & Kolter, T. 1997 Biochemistry of glycosphingolipid degradation. Clin. Chim. Acta 266, 51-61.
46. Sandhoff, K. & Kolter, T. 2003 Biosynthesis and degradation of mammalian glycosphingolipids. Phil. Trans. R. Soc. Lond. B 358, 847-861. (DOI 10.1098/rstb.2003.1265.)
47. Sandhoff, K. & Van Echten, G. 1993 Ganglioside metabolism - topology and regulation. Adv. Lipid Res. 26, 119-142.
48. Sango, K. (and 10 others) 1995 Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11, 170-176.
49. Schapiro, F. B., Lingwood, C., Furuya, W. & Grinstein, S. 1998 pH-independent retrograde targeting of glycolipids to the Golgi complex. Am. J. Physiol. 274, C319-C332.
50. Suzuki, K. & Mansson, J.-E. 1998 Animal models of lysosomal disease: an overview. J. Inherit. Metab. Dis. 21, 540-547.
51. Suzuki, K. & Proia, R. L. 1998 Mouse models of human lysosomal diseases. Brain Pathol. 8, 195-215.
52. Tanaka, J., Garcia, J. H., Max, S. R., Viloria, J. E., Kamijyo, Y., McLaren, N. K., Cornblath, M. & Brady, R. O. 1975 Cerebral sponginess and GM3 gangliosidosis; ultrastructure and probable pathogenesis. J. Neuropathol. Exp. Neurol. 34, 249-262.
53. Tybulewicz, V. L. (and 13 others) 1992 Animal models of Gaucher's disease from targetted disruption of mouse gluco-cerebrosidase gene. Nature 357, 407-410.
54. Van Echten, G. & Sandhoff, K. 1993 Ganglioside metabolism. Enzymology, topology, and regulation. J. Biol. Chem. 268, 5341-5344.
55. Vunnam, R. R. & Radin, N. S. 1980 Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. -Phys.-Lipids 26, 265-278.
56. Wada, R., Tifft, C. J. & Proia, R. L. 2000 Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl Acad. Sci. USA 97, 10 954-10 959.
57. Yamanaka, S., Johnson, M. D., Grinberg, A., Westphal, H., Crawley, J. N., Taniike, M., Suzuki, K. & Proia, R. L. 1994 Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl Acad. Sci. USA 91, 9975-9979.
58. Yamashita, T., Wada, R., Sasaki, T., Deng, C., Bierfreund, U., Sandhoff, K. & Proia, R. L. 1999 A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl Acad. Sci. USA 96, 9142-9147.